Focal eosinophilic necrosis on superparamagnetic iron oxide-enhanced MRI

Eun-Suk Cho1, Jeong-Sik Yu, Myeong-Jin Kim

  • 1Department of Radiology, Yonsei University College of Medicine, Gangnam Severance Hospital, 612 Eonjuro, Gangnam-gu, Seoul 135-720, Republic of Korea.

Abstract

Insights

Superparamagnetic iron oxide (SPIO)-enhanced MRI effectively distinguishes focal eosinophilic necrosis (FEN) from liver metastases. SPIO-enhanced T2-weighted imaging shows signal loss in FEN, aiding differential diagnosis.

Area of Science:

  • Radiology
  • Medical Imaging
  • Hepatology

Background:

  • Distinguishing focal eosinophilic necrosis (FEN) from hepatic metastases is crucial for patient management.
  • Superparamagnetic iron oxide (SPIO)-enhanced MRI offers potential for improved tissue characterization.

Purpose of the Study:

  • To evaluate the diagnostic utility of SPIO-enhanced MRI in differentiating FEN from hepatic metastases.

Main Methods:

  • Retrospective analysis of 41 FEN and 40 hepatic metastasis cases using unenhanced and SPIO-enhanced T2-weighted MRI.
  • Lesion classification based on signal intensity changes (categories 1-4) and measurement of contrast-to-noise ratio (CNR).
  • Comparison of Kupffer cell counts in FEN biopsy specimens versus background liver parenchyma.

Main Results:

  • Hepatic metastases consistently appeared as category 4 (significant signal loss), while FEN showed varied signal loss patterns (categories 1-4).
  • FEN demonstrated a decrease in CNR post-SPIO administration (p < 0.05), whereas metastases showed an increase (p < 0.05).
  • FEN biopsy specimens revealed significantly higher Kupffer cell counts compared to normal liver tissue (174.7 vs. 23.7 cells/hpf).

Conclusions:

  • SPIO-enhanced T2-weighted MRI effectively differentiates FEN from hepatic metastases based on signal intensity and CNR changes.
  • The observed signal reduction in FEN is likely related to its higher Kupffer cell content.
  • SPIO-enhanced MRI is a valuable tool for the differential diagnosis of FEN and liver metastases.